Traders Buy Gilead Sciences (GILD) on Weakness

Investors bought shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading on Thursday. $87.52 million flowed into the stock on the tick-up and $55.21 million flowed out of the stock on the tick-down, for a money net flow of $32.31 million into the stock. Of all companies tracked, Gilead Sciences had the 32nd highest net in-flow for the day. Gilead Sciences traded down ($0.64) for the day and closed at $67.53

A number of research firms have recently weighed in on GILD. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price for the company in a research report on Monday, February 5th. Leerink Swann reduced their target price on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a research report on Wednesday, February 7th. Maxim Group set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, February 6th. Citigroup reissued a “buy” rating and set a $105.00 target price (up from $103.00) on shares of Gilead Sciences in a research report on Thursday, February 8th. Finally, Bank of America increased their target price on shares of Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $88.14.

The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84. The firm has a market cap of $87.81 billion, a P/E ratio of 7.87, a price-to-earnings-growth ratio of -5.87 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The firm had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the previous year, the business earned $2.23 earnings per share. The firm’s revenue for the quarter was down 21.8% on a year-over-year basis. equities analysts anticipate that Gilead Sciences, Inc. will post 5.75 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be issued a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 3.38%. The ex-dividend date of this dividend is Thursday, June 14th. Gilead Sciences’s payout ratio is 26.64%.

In other news, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares in the company, valued at approximately $1,907,282.19. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director John Francis Cogan sold 5,836 shares of the firm’s stock in a transaction on Friday, May 4th. The shares were sold at an average price of $65.09, for a total transaction of $379,865.24. Following the sale, the director now owns 58,455 shares in the company, valued at approximately $3,804,835.95. The disclosure for this sale can be found here. Over the last three months, insiders sold 226,667 shares of company stock valued at $17,060,854. Insiders own 1.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Archford Capital Strategies LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $106,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter valued at $133,000. Certified Advisory Corp purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $133,000. Advisors Preferred LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $140,000. Finally, Stelac Advisory Services LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $141,000. Hedge funds and other institutional investors own 77.72% of the company’s stock.

About Gilead Sciences

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply